A Microdose Study of TTX-MC138-NODAGA-Cu64 in Subjects With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single-center, single-arm, phase 0, microdose study in subjects with
advanced solid tumors and radiographically confirmed metastases.
The study will evaluate delivery of TTX-MC138-NODAGA-Cu64 radiographically and establish the
PK and biodistribution of TTX-MC138-NODAGA-Cu64 as determined by PET-MRI. The study consists
of 3 parts: a screening period, dosing period, and follow-up period. The estimated total
duration of the study is approximately 46 days.
Approximately 12 subjects with advanced metastatic solid tumors will be enrolled at 1 single
site.